Telix Pharmaceuticals Limited ADR (TLX)
NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.84B
- P/E (TTM)
- 83.70
- EPS (TTM)
- $0.10
- Dividend yield
- None
- 52-week range
- 6.28 – 13.11
- Day range
- 8.37 – 8.70
- Volume / Avg
- 269.43K / 356.74K
- Beta
- —
- Shares outstanding
- 339.78M
52-week range
TLX stock today
Telix Pharmaceuticals (TLX) closed at $8.37 on Nov 20, down 3.90% (-$0.34), versus the S&P 500's 3.70% decline. At this level, TLX sits in the middle of its 52-week range of $6.28 to $13.11: 36.2% below the high, set on Sep 15, 2026 and 33.3% above the low. TLX is up 11.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.1%.
Telix Pharmaceuticals trades at 83.7x its trailing twelve-month earnings per share of $0.10.
Summary generated from market data by MetaCap's automated system. Methodology
About Telix Pharmaceuticals
Company profileTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D
- Headquarters
- North Melbourne, VIC
- Employees
- 1,120
- Website
- telixpharma.com
Financial highlights
Full financialsIn fiscal 2025, Telix Pharmaceuticals generated $803.8 million in revenue, up 55.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Telix Pharmaceuticals reported a net loss of $7.1 million, compared with net income of $33.7 million a year earlier. Gross margin was 53.1% (down from 65.1%) and operating margin 3.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $803.79M | $516.55M | $332.98M |
| Growth | +55.61% | +55.13% | — |
| Net income | $-7.13M | $33.69M | $4.21M |
| EPS (diluted) | $-0.0211 | $0.0976 | $0.013 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$19.66+134.89%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
TLX news
All TLX news- Telix to Participate in UBS Global Biopharma ConferencePR Newswire
- Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027NasdaqTLX, HEI.A
- Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline ProgramsNasdaqTLX, LEN.B
- Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 GuidanceNasdaq
- Telix Reports Third Quarter 2026 Financial PerformanceGlobeNewswire
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeNasdaqGEHC, LNTH, TLX, RADX
- Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.GlobeNewswire
- FDA Drug Approvals In September 2026NasdaqABBV, AZN, INCY, IONS
Telix Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLSSELLAS Life Sciences Group Inc. | 13.66 | -8.08% | $2.78B | vs TLX |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs TLX |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs TLX |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs TLX |
| ZLABZai Lab Limited ADR | 21.03 | -4.06% | $2.63B | vs TLX |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs TLX |
| XERSXeris Biopharma Holdings Inc. | 16.97 | +2.11% | $3.10B | vs TLX |
| VKTXViking Therapeutics Inc. | 24.77 | -4.14% | $3.16B | vs TLX |
Indexes, lists and sector
Telix Pharmaceuticals stock FAQ
What is Telix Pharmaceuticals's stock price today?
TLX last traded at $8.37 as of Nov 20, 4:00 PM EST, down 3.90% on the day. Prices are delayed at least 15 minutes.
What is TLX's P/E ratio?
TLX trades at a trailing P/E ratio of 83.70.
Who is Telix Pharmaceuticals's CEO?
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Limited ADR, which has about 1,120 employees.
What is the TLX 52-week high?
The 52-week high for TLX is $13.11 and the 52-week low is $6.28. The stock is currently 36.2% below its high.